Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, ChinaClinical College of Medicine, Shandong University, Jinan, 250021, China
刊名
Chinese Journal of Cancer Prevention and Treatment
年份
2019
卷号
Vol.26 No.21
页码
1622
ISSN
1673-5269
摘要
OBJECTIVE: Radiation-induced oral mucositis is the most several non-hematologic adverse reactions during radiotherapy of head and neck carcinoma. Nasopharyngeal carcinoma is the most common head and neck carcinoma in China. This study aimed to investigate the efficacy and safty of Xuebijing injection in treatment of RTOM on nasopharyngeal carcinoma. METHODSP: A total of 49 patients with nasopharyngeal carcinoma treated from June 2013 to July 2018 in Shandong Cancer Hospital were retrospective an...更多
OBJECTIVE: Radiation-induced oral mucositis is the most several non-hematologic adverse reactions during radiotherapy of head and neck carcinoma. Nasopharyngeal carcinoma is the most common head and neck carcinoma in China. This study aimed to investigate the efficacy and safty of Xuebijing injection in treatment of RTOM on nasopharyngeal carcinoma. METHODSP: A total of 49 patients with nasopharyngeal carcinoma treated from June 2013 to July 2018 in Shandong Cancer Hospital were retrospective analysised. Totally 23 patients in control group were treated with Kangfuxin solution, while XBJI were additionally used in observation group with 26 patients. Both groups were treated with intensity-modulated radiation therapy. Degree of RTOM and Hematological adverse reactions during therapy was compared. RESULTS: Patients in both groups suffered from varying degree of RTOM. No grade 4 RTOM was happened in both group of patients. Three weeks after radiotherapy, grade 0-3 mucositis occurred in 2, 15, 8 and 1 cases in the observation group and 1, 7, 12 and 3 cases in the control group. Four weeks after radiotherapy, grade 0-3 mucositis occurred in 0, 13, 13 and 0 cases in the observation group and 0, 2, 16 and 5 cases in the control group. Five weeks after radiotherapy, grade 0-3 mucositis occurred in 0, 12, 12 and 2 cases in the observation group and 0, 0, 16 and 7 cases in the control group. Six weeks after radiotherapy, grade 0-3 mucositis occurred in 1, 9, 15 and 1 cases in the observation group and 0, 1, 18 and 4 cases in the control group. The level of oral mucositis in observation group was significantly superior to control group at each time point. CONCLUSIONS: XBJI can significantly decrease the occurrence rate of RTOM and inhibit the level of oral mucositis. XBJI can delay the occurrence time of oral mucositis and is safe in clinical application.收起
